In this review, we discuss the preclinical and clinical evidence demonstrating the involvement of SFKs in imatinib resistance and the progression of CML and Ph+ ALL, as well as the potential role of dual SFK/BCR-ABL inhibition in the management of these diseases. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.